Epista Launches Major Clinical Data Remediation Program with Global Pharma Leader
Multi-phase initiative will remediate over 4 million clinical records across 800+ studies, ensuring inspection-ready data for global biopharma leader's digital transformation.
KING OF PRUSSIA, Pa., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Epista Life Science today announced one of the pharmaceutical industry's most comprehensive clinical data remediation programs, a multi-phase initiative spanning more than 800 studies, 43,000 study sites, and over four million clinical documents. The program will prepare a leading global biopharmaceutical innovator for the successful implementation of a next-generation Clinical Trial Management System (CTMS) while establishing enterprise-wide data governance standards.
The remediation program will deliver three critical outcomes that directly support the client's CTMS migration and long-term operational excellence:
- Enhanced TMF Oversight - Comprehensive reporting and monitoring systems that provide real-time visibility into Trial Master File health, ensuring regulatory compliance and inspection readiness
- CTMS Migration Readiness - Fully remediated, standardized data that guarantees seamless implementation of next-generation clinical trial management systems with zero legacy data issues
-
Future-Ready Data Infrastructure - Enterprise-wide governance standards that ensure data quality and consistency, positioning the organization to leverage advanced analytics and AI-driven insights.
The program leverages Epista's proven remediation methodology in partnership with the DNANexus platform, enabling accelerated data quality improvements at an unprecedented scale.
"This represents the largest clinical data remediation program Epista has undertaken, and it's solving one of the most critical challenges in clinical operations today," said Toni Lakin-Ritter, Managing Director, Epista Life Science US. "You cannot successfully implement a modern CTMS on top of inconsistent, unreliable data. This program ensures our client's digital transformation is built on a foundation of trusted, inspection-ready information that will support their operations for years to come."
The initiative builds on Epista's expanding relationship with the client, where the consultancy has previously supported inspection readiness, TMF completeness, and business continuity during mergers and acquisitions.
The program will include comprehensive data quality assessments, coordinated remediation waves across key clinical domains, and implementation of a sustainable governance framework. A structured hypercare phase will ensure adoption and continuous quality monitoring, delivering both immediate impact and long-term operational value.
“Our vision is to create a data environment that not only supports compliance and operational excellence but also fuels innovation for the future of clinical trials," said the client's Director of Clinical Records & Information Management. “With Epista leading this effort, we are confident in achieving better TMF oversight and reporting, a solid foundation for CTMS, and the enterprise-wide governance needed to enable AI-driven insights. This partnership is more than a project — it is a transformation of how we manage and trust our data.”
The remediation program is expected to reduce study startup times, minimize inspection risk, and enable real-time operational insights across the enterprise once the new CTMS is fully implemented.
About Epista Life Science
Epista Life Science is a global consultancy dedicated to empowering life science companies to accelerate innovation while maintaining compliance. With expertise spanning data integrity, digital transformation, and regulatory frameworks, Epista partners with clients to turn compliance challenges into business opportunities.
A PDF accompanying this announcement is available at http://ml.globenewswire.com/Resource/Download/10bf5fe0-5238-455b-9df4-2b958ec8ad4e
Media Contact: Oliver Pearce Head of Marketing Epista Life Science Oli@epista.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
